# US 6,726,895 B2 · Method of imaging cell death in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,895 B2
- Document ID: US6726895B2
- Status: Granted
- Kind: B2
- Application number: 10/114,926
- Filed: 2002-04-03
- Published: 2003-01-02
- Granted: 2004-04-27
- Earliest claimed: 2001-04-03
- Assignees: The Board of Trustees of the Leland Stanford Junior University; Theseus Imaging Corporation
- Inventors: H. William Strauss; Francis G. Blankenberg; Allan M. Green; Neil Steinmetz
- Web page: https://patentgrep.com/patent/US6726895B2

## CPC

- A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}
- A61K 51/087: {the peptide being an annexin, e.g. annexin V}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of imaging apoptosis in vivo, using radiolabeled annexin, is described. Methods for tumor radiotherapy are also provided.

## Claims

### Claim 1

A method of tumor radiotherapy comprising administering to a mammalian subject having a tumor involving a nucleated cell an effective tumor reducing amount of a composition comprising an annexin coupled with a therapeutic radioisotope.

### Claim 2 (depends on 1)

The method of claim 1, used in conjunction with total body irradiation or targeted external irradiation.

### Claim 3 (depends on 1)

The method of claim 1, used in conjunction with targeted internal irradiation.

### Claim 4 (depends on 1)

The method of claim 1, used in conjunction with a treatment employing at least one chemotherapeutic agent.

### Claim 5 (depends on 4)

The method of claim 4, wherein the chemotherapeutic agent is selected from the group consisting of dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.

### Claim 6 (depends on 1)

The method of claim 1, used in conjunction with total body irradiation and with a treatment employing at least one chemotherapeutic agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the chemotherapeutic agent is selected from the group consisting of dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.

### Claim 8 (depends on 1)

The method of claim 1, used in conjunction with an apoptosis inducing agent selected from the group consisting of TNF, TRAIL and Fas.

### Claim 9 (depends on 1)

The method of claim 1, used in conjunction with an apoptosis inducing agent selected from the group consisting of a TNF-binding antibody, a TRAIL-binding antibody and a Fas-binding antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutic radioisotope is selected from the group consisting of 103Pd, 186Re, 188Re, 90Y, 153Sm, 159Gd, and 166Ho.

### Claim 11 (depends on 1)

The method of claim 1, wherein the annexin is annexin V or a fragment thereof.

### Claim 12

A method of tumor radiotherapy, comprising
treating a subject having a tumor involving a nucleated cell with a chemotherapeutic agent; and
administering to the treated subject an effective tumor reducing amount of a composition comprising an annexin coupled with a therapeutic radioisotope.

### Claim 13 (depends on 12)

The method of claim 12, wherein the chemotherapeutic agent is selected from the group consisting of dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.

### Claim 14 (depends on 12)

The method of claim 12, further comprising administering to the subject an apoptosis inducing agent selected from the group consisting of TNF, TRAIL and Fas.

### Claim 15 (depends on 12)

The method of claim 12, further comprising administering to the subject an apoptosis inducing agent selected from the group consisting of a TNF-binding antibody, a TRAIL-binding antibody and a Fas-binding antibody.

### Claim 16 (depends on 12)

The method of claim 12, wherein the therapeutic radioisotope is selected from the group consisting of 103Pd, 186Re, 188Re, 90Y, 153Sm, 159Gd, and 166Ho.

### Claim 17 (depends on 12)

The method of claim 12, wherein the annexin is annexin V or a fragment thereof.
